Pharmacovigilance Risk Assessment Committee (PRAC)

  • Email
  • Help

The Pharmacovigilance Risk Assessment Committee (PRAC) is the European Medicines Agency's (EMA) committee responsible for assessing and monitoring the safety of human medicines.

The PRAC was formally established in line with the pharmacovigilance legislation which came into effect in 2012 to help strengthen the safety monitoring of medicines across Europe.

Role of the PRAC

The PRAC is responsible for assessing all aspects of risk management of human medicines, including:

  • the detection, assessment, minimisation and communication of the risk of adverse reactions, while taking the therapeutic effect of the medicine into account;
  • design and evaluation of post-authorisation safety studies;
  • pharmacovigilance audit.

The PRAC provides recommendations on questions on pharmacovigilance and risk management systems, including the monitoring of their effectiveness, to the:

For full details, see:

More information

How useful is this page?

Average rating:

 Based on 9 ratings

Add your rating:

See all ratings
1 ratings
0 ratings
0 ratings
5 ratings
3 ratings

Related content

Related documents

Scientific publications

Contact point:

PRAC Secretariat
European Medicines Agency
30 Churchill Place
Canary Wharf
London E14 5EU
United Kingdom